 Connection
Mary Weiser-Evans to Biomarkers
This is a "connection" page, showing publications Mary Weiser-Evans has written about Biomarkers.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.077 |
|
|
|
-
Okamura K, Lu S, He Z, Altmann C, Montford JR, Li AS, Lucia MS, Orlicky DJ, Weiser-Evans M, Faubel S. IL-6 mediates the hepatic acute phase response after prerenal azotemia in a clinically defined murine model. Am J Physiol Renal Physiol. 2023 09 01; 325(3):F328-F344.
Score: 0.028
-
Ravichandran K, Holditch S, Brown CN, Wang Q, Ozkok A, Weiser-Evans MC, Nemenoff R, Miyazaki M, Thiessen-Philbrook H, Parikh CR, Ljubanovic D, Edelstein CL. IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol. 2018 03 01; 314(3):F356-F366.
Score: 0.019
-
Ravichandran K, Wang Q, Ozkok A, Jani A, Li H, He Z, Ljubanovic D, Weiser-Evans MC, Nemenoff RA, Edelstein CL. CD4 T cell knockout does not protect against kidney injury and worsens cancer. J Mol Med (Berl). 2016 Apr; 94(4):443-55.
Score: 0.016
-
Ostriker A, Horita HN, Poczobutt J, Weiser-Evans MC, Nemenoff RA. Vascular smooth muscle cell-derived transforming growth factor-? promotes maturation of activated, neointima lesion-like macrophages. Arterioscler Thromb Vasc Biol. 2014 Apr; 34(4):877-86.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|